Myelin Associated Glycoprotein (MAG) Antibody
Anti-Myelin Associated Glycoprotein (MAG) peripheral neuropathy is a neurologic auto-immune disorder. Antibodies specific to Schwann cells attack nervous tissue and cause the surrounding region to lose function and create sensory and motor problems. The antibodies are uniquely monoclonal IgM type. This specific disorder accounts for approximately 10% of peripheral neuropathy patients. Symptoms include muscle weakness and other motor deficits such as hand tremors and trouble walking, as well as sensory ataxia most common in the distal extremities in a symmetric distribution. Treatments exist for Anti-MAG peripheral neuropathy, for example strength-building exercises and/or targeted drug therapies. The drug therapies are targeted towards reducing the production of antibody and the number of plasma cells that produce it.
Anti-MAG antibodies disrupt myelin associated glycoprotein function by binding to the external domain and inhibiting signaling. These glycoproteins play a significant role in many signaling cascades, including the cascade that causes Schwann cells to create myelin. The anti-MAG antibody titer is correlated to the degree of demyelination.
- Aids in diagnosis of Anti-MAG peripheral neuropathy
- Aid in diagnosis of other neuropathies associated with demyelination
- MAG IgM concentrations elevated at 1000 Titer Units (TU) or higher suggest active demyelination in peripheral neuropathy
- MAG IgM concentrations below 1000 TU do not suggest antibody-associated (anti-MAG) peripheral neuropathy
Negative
Semi-quantitative: <1000 TU
Serum (SST) or plasma (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- J Neurol. 1996 Jan;243(1):34-43. [PMID: 8869385]
- Curr Opin Neurol. 2006 Oct;19(5):458-63. [PMID: 16969155]
- Ann Neurol. 1989 Oct;26(4):543-50. [PMID: 2479332]
- Crit Rev Neurobiol. 1988;3(4):301-32. [PMID: 2458847]
- Neurol Clin. 1992 Aug;10(3):713-34. [PMID: 1323750]